Anti-microbial/Anti-fungal Tests Market
Market Survey on Anti-microbial/Anti-fungal Tests Market Covering Sales Outlook, Up-to-date Key Trends, Market Size and Forecast, Per Capita Expenditure, Company Share, Brand Share, Regulations, Reimbursement Scenario, Epidemiology, Procedure Numbers, and Pipeline Assessment
An In-depth Market Insights of Anti-microbial/Anti-fungal Tests Market including Molecular Based Tests, Phenotypic Resistance Tests, Complex Test Panels, Mass Spectrometry, and Rapid Diagnostic Tests Covering 30+ Countries like United States, United Kingdom, Germany, France, Norway, Sweden, Saudi Arabia, United Arab Emirates, Japan, Korea, Australia, New Zealand, and Others
Anti-microbial/Anti-fungal Tests Market Outlook (2022 to 2032)
[268 Pages Report] The global anti-microbial/anti-fungal tests market is expected to reach US$ 2.5 Billion by the end of 2022. Growth in the market is predicted to expand at a CAGR rate of 5.7% and surpass ~US$ 4.5 Billion by 2032. Based on test type, the molecular-based tests led the market with a share of nearly 53.5% in 2021.
Attributes |
Key Insights |
Anti-microbial/Anti-fungal Tests Market Value 2021 |
US$ 2.4 Billion |
Estimated Market Size 2022 |
US$ 2.5 Billion |
Projected Market Value 2032 |
US$ 4.5 Billion |
CAGR 2022 to 2032 |
5.7% |
Market Share of Top 5 Countries |
55.0% |
Microorganism screening to create novel antibiotics has been successfully pursued for numerous years by the researcher. Fungus and bacteria often generate antibiotics. Bacteria are consumed in a variety of fields, including agriculture. In the pharmaceutical and veterinary industries, an antimicrobial is a substance that kills or inhibits bacterial growth.
Antibiotics are employed against antifungals, and bacteria are utilized against fungi in these cases. Antimicrobial chemotherapeutic use antimicrobial drugs to combat infection, and antimicrobial prophylaxis uses antimicrobial medicines to prevent infection. Antimicrobial susceptibility tests can help physicians choose the best medicine and dosage for difficult-to-treat infections.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Sales Analysis of Anti-microbial/Anti-fungal Tests Market from 2012 to 2021 Vs Demand Outlook for 2022 to 2032
As per Future Market Insights (FMI), the anti-microbial/anti-fungal tests market was approximately 15.4% of the overall ~US$ 15.6 Billion global rapid testing kits market in 2021. Overall sales in the anti-microbial/anti-fungal tests market surged at a CAGR of 5.6% from 2012 to 2021.
Growth in the market is primarily attributed to the increased prevalence of infectious diseases across the globe. Furthermore, rising rates of surgical site infections and other related issues are propelling sales in the antimicrobial antifungal test market. Further, advancements in biotechnology and in diagnostic procedures are facilitating growth in the market.
As a number of pathogenic bacteria develop antibiotic resistance and novel forms of resistance emerge, healthcare professionals are focusing on antimicrobial susceptibility testing (AST). Minimum inhibitory concentrations (MICs) are provided by a rapid multiplexed AST platform at a reasonable cost, allowing for the rapid determination of effective targeted therapy. This is resulting in shorter hospital stays, fewer laboratory tests, and lower morbidity and mortality, as well as associated healthcare costs.
The market witnessed prolific growth as the use of antibiotics and antifungal skyrocketed. Further, nosocomial bacterial superinfections are more common than community-acquired coinfections. This is particularly among ICU patients and those taking immunosuppressive therapy. On the back of these factors, the global anti-microbial/anti-fungal tests market is expected to grow at a CAGR of 5.7% during the forecast period.
What are the Key Opportunities in the Anti-microbial/Anti-fungal Tests Kit Market?
- Favorable Government Initiatives and Awareness Programs to Fuel the Growth
Favorable government initiatives and the development of healthcare infrastructure across the globe is the key factor propelling sales in the global anti-microbial/anti-fungal tests kit market. Advancements in point-of-care (POC) detection methods that enable decentralised, quick, sensitive, low-cost COVID-19 infection diagnostics are spuuring the growth in the market.
Rising awareness by government bodies has positively impacted manufacturers and healthcare service providers. For instance, WAAW was formerly known as World Antibiotic Awareness Week, which is now changed to World Antimicrobial Awareness Week in 2020. This reflects WAAW's expanded scope, which now includes all antimicrobials such as antifungals, antibiotics, antiparasitics, and antivirals.
What are the Factors Restraining Demand for Anti-microbial/Anti-fungal Tests?
The lack of an innovation culture and stringent regulatory approvals might hamper the demand in the market. In general, healthcare providers and medical workers are risk-averse and resistant to policy reforms. In the realm of in-vitro diagnostics, there have been numerous instances where physicians have been highly reluctant to advance. Furthermore, the administration and organization of diagnostic services may further restrict the market in the forecast period's coming years.
Further, the complexity in interpreting the paradoxical growth phenomenon seen with echinocandins and yeasts (which differs from the trailing effect) and uncertainty for caspofungin testing is due to the molecule's lack of stability in culture media. These factors cumulatively might negatively affect the growth in the anti-microbial/anti-fungal tests market.
Country-wise Insights
How will the Sales in the USA Anti-microbial/Anti-fungal Tests Market Increase?
Growing Preference for Diagnostic Tests to Boost the Sales
The USA dominated the North American anti-microbial/anti-fungal tests market with a total share of about 89.4% in 2021. Growth in the market is primarily underpinned by the growing preference for diagnostic tests recommended by physicians before any type of treatment. Furthermore, widespread awareness of the adverse effects of particular medications, and patients frequently prefer to be fully diagnosed before seeking treatment.
Will China Retain its Dominance in Anti-microbial/Anti-fungal Tests Market?
Rising Prevalence of NIC and Diabetes Mellitus to Facilitate the Growth in China
China held approximately 7.5% share in the global anti-microbial/anti-fungal tests market in 2021, as per FMI. Sales in the market are projected to display growth at a CAGR of 7.1% during the forecast period.
Due to the increased number of immunocompromised individuals, invasive fungal infections (IFIs), especially those caused by uncommon yeasts, are becoming more common. Invasive candidiasis is the key concern with significant morbidity and mortality.
It affects patients of all ages, including those with malignancies, non-immunocompromised (NIC) and HIV-negative immunocompromised (IC) patients, individuals among the severely ill, typically hospitalised to an intensive care unit (ICU), or diagnosed with diabetes mellitus or uncontrolled hyperglycaemia needing invasive mechanical ventilation.
How Big is the Opportunity in Germany's Anti-microbial/Anti-fungal Tests Market?
Germany Anti-microbial/Anti-fungal Tests Market to Gain from Rising Incidence of Fungal Infection
Germany is set to exhibit a CAGR growth of nearly 7.1% in the Europe anti-microbial/anti-fungal tests market during the forecast period. Candida glabrata is the second most common fungal infection in Germany, causing candidaemia and invasive candidiasis.
This yeast is known for its quick acquisition of antifungal medication resistance. Furthermore, with the increasing prevalence of chronic and infectious diseases, the ageing population will demand the anti-microbial/anti-fungal tests market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Category-wise Insights
Which Anti-microbial/Anti-fungal Tests Type is Driving the Growth?
Molecular-Based Tests to Gain Immense Traction through 2022 & Beyond
Molecular-based tests are expected to lead the market, registering growth at a CAGR of 5.3% during the forecast period. The segment is expected to account for a share of more than 50.0% in the global anti-microbial/anti-fungal tests market. Owing to their factors of increasing susceptibility, minimization of false positive results, better turnaround time, and possesses wide applications.
Based on infection, antimicrobial resistance held a revenue share of 48% in 2021 and is expected to display gradual growth over the forecast period. Antimicrobial resistance (AMR) emerges when fungi, viruses, bacteria, and parasites evolve over a period. Therefore it shows no longer responds to antibiotics treatment, making infections more challenging to treat and increasing the risk of disease spread, major illness, and death. This is expected to fuel revenue growth over the forecast period.
Which is the Leading End User in Anti-microbial/Anti-fungal Tests Market?
Nearly 2 out of 5 Sales are Contributed by Hospitals
As per FMI, hospitals held the market with the highest share value of 36.9% and are expected to maintain the lead over the upcoming decade. Increasing hospital-acquired infections and increasing inpatient admissions are propelling sales of the overall anti-microbial/anti-fungal tests market.
Competitive Landscape
With several competitors in the anti-microbial/anti-fungal tests market, the overall market is fragmented. To meet consumer demand and expand their customer base, these companies are implementing methods such as mergers and acquisitions, partnerships and collaborations, and new product launches.
- In July 2022, Roche announced that Elecsys HCV Duo immunoassay is now available in countries that accept the CE Mark. Elecsys HCV Duo is the only immunoassay on the market that can determine hepatitis C virus (HCV) antigen and antibody status from a single human plasma or serum sample.
- In June 2022, Meridian Bioscience, Inc., a global leader in diagnostic testing solutions and life science raw materials, introduced two new sample-specific master mixes, Lyo-Ready Direct DNA qPCR Stool Mix and Lyo-Ready Direct RNA/DNA qPCR Stool Mix. These novel master mixes increase the molecular detection of DNA and RNA from crude faecal materials while allowing diagnostic procedures to be room temperature stabilised.
Report Scope as per Anti-microbial/Anti-fungal Tests Industry Analysis
Attribute |
Details |
Estimated Market Size 2022 |
US$ 2.5 Billion |
Projected Market Value 2032 |
US$ 4.5 Billion |
CAGR 2022 to 2032 |
5.7% |
Forecast Period |
2012 to 2021 |
Historical Data Available for |
2022 to 2032 |
Market Analysis |
US$ Million for Value |
Key Regions Covered |
North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa |
Key Countries Covered |
USA, Canada, Brazil, Mexico, Argentina, UK, Germany, Italy, Russia, Spain, France, BENELUX, Nordic Countries, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC Countries, South Africa, and North Africa |
Key Market Segments Covered |
Tests, Infection, End User, and Region |
Key Companies Profiled |
|
Key Market Segments Covered in Anti-microbial/Anti-fungal Tests Industry Research
By Tests Type:
- Molecular Based Tests
- PCR Test
- DNA Microarray
- Phenotypic Resistance Tests
- Complex Test Panels
- Mass Spectrometry
- Rapid Diagnostic Tests
- E-Test Antibiotic/Antifungal Strips
- Biosensor Platforms
By Infection Type:
- Antimicrobial Resistance
- Methicillin-Resistant Staphylococcus Aureus
- Vancomycin-Resistant Enterococcus
- Multi-Drug-Resistant Mycobacterium tuberculosis
- Carbapenem-Resistant Enterobacteriaceae gut bacteria
- Microbial Infection
- Antifungal Resistance
- Candida infections
- Aspergillus infection
- Fusariosis
- Others
- Fungal Infection
By End User:
- Hospitals
- Ambulatory Surgical Centers
- Clinics
- Community Health Centers
- Reference Laboratories
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa (MEA)
Frequently Asked Questions
How much was the anti-microbial/anti-fungal tests market worth in 2021?
The global anti-microbial/anti-fungal tests market is worth US$ 2.4 Billion in 2021 and is set to expand 1.7X over the next ten years.
What is the sales forecast for the anti-microbial/anti-fungal tests market through 2032?
The anti-microbial/anti-fungal tests market is expected to reach US$ 4.5 Billion by the end of 2032, with sales revenue expected to register a 5.7% CAGR.
What are the key trends shaping the anti-microbial/anti-fungal tests market?
The growing geriatric population and innovative product development, increasing prevalence of antimicrobial resistance cases are some of the key trends in this market.
Which are the top five countries driving demand for anti-microbial/anti-fungal tests?
USA, India, China, Germany, and Japan are expected to drive demand for the anti-microbial/anti-fungal tests industry.
What is the North American market outlook for anti-microbial/anti-fungal tests?
North America is one of the key markets for anti-microbial/anti-fungal tests, with the USA accounting for about 89.4% of the North American anti-microbial/anti-fungal tests market in the year 2021.
At what percentage is the demand for anti-microbial/anti-fungal tests expected to register growth in Europe?
Demand for anti-microbial/anti-fungal tests in Europe is expected to register a growth of 5.0% CAGR over the next ten years.
At what percentage is the demand for anti-microbial/anti-fungal tests expected to register growth in MEA?
Demand for anti-microbial/anti-fungal tests in MEA is expected to register a growth of 4.5% over the next ten years.
Which countries are the key producers of anti-microbial/anti-fungal tests?
China and the USA, Germany are the key producers of anti-microbial/anti-fungal tests.
Who are the key players in the anti-microbial/anti-fungal tests market sphere?
Abbott Laboratories, bioMérieux SA, Bio-Rad Laboratories Inc., Bruker Corporation, Danaher Corporation, Erba Mannheim, F. Hoffmann-La Roche AG, Luminex Corporation, Meridian Bioscience Inc., Norgen Biotek Corp., Omega Diagnostics Group Plc., Qiagen N.V., Quidel Corporation, and Thermo Fisher Scientific Inc., are some of the key players in the anti-microbial/anti-fungal tests industry.
Table of Content
1. Executive Summary | Anti-microbial/Anti-fungal Tests Market 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Key Success Factors 4.1. Epidemiology of Key Indication, By Region 4.2. Key Promotional Strategies 4.3. Patient Journey 4.4. Regulatory Scenario 4.5. Reimbursement Landscape 4.6. PESTEL analysis 4.7. Porter’s analysis 4.8. Value Chain 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare GDP Growth Overview 5.2. Forecast Factors - Relevance & Impact 5.2.1. Rising Prevalence of infectious diseases. 5.2.2. Increasing Awareness and Adoption. 5.2.3. Increase in rapid diagnostics tests. 5.2.4. Increasing prevalence of antimicrobial resistance patients. 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 5.4. Global Supply Demand Analysis 6. COVID-19 Crisis - Crisis Analysis 6.1. COVID-19 and Impact Analysis 6.2. 2021 Market Scenario 6.2.1. By Tests Type 6.2.2. By Infection Type 6.2.3. By End User 6.2.4. By Region 7. Global Market Demand (in Value or Size in US$ Million) Analysis 2012 to 2021 and Forecast, 2022 to 2032 7.1. Historical Market Value (US$ Million) Analysis, 2012 to 2021 7.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2032 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Tests Type 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) Analysis By Tests Type, 2012 to 2021 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Tests Type, 2022 to 2032 8.3.1. Molecular-Based Tests 8.3.1.1. PCR Test 8.3.1.2. DNA Microarray 8.3.2. Phenotypic Resistance Tests 8.3.3. Complex Test Panels 8.3.4. Mass Spectrometry 8.3.5. Rapid Diagnostic Tests 8.3.5.1. E-Test Antibiotic/Antifungal Strips 8.3.5.2. Biosensor Platforms 8.4. Market Attractiveness Analysis By Tests Type 9. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Infection Type 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) Analysis, By Infection Type, 2012 to 2021 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Infection Type, 2022 to 2032 9.3.1. Antimicrobial Resistance 9.3.1.1. Methicillin-Resistant Staphylococcus Aureus 9.3.1.2. Vancomycin-Resistant Enterococcus 9.3.1.3. Multi-Drug-Resistant Mycobacterium tuberculosis 9.3.1.4. Carbapenem-Resistant Enterobacteriaceae gut bacteria 9.3.2. Microbial Infection 9.3.3. Antifungal Resistance 9.3.3.1. Candida infections 9.3.3.2. Aspergillus infection 9.3.3.3. Fusariosis 9.3.3.4. Others 9.3.4. Fungal Infection 9.4. Market Attractiveness Analysis By Infection Type 10. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) Analysis, By End User, 2012 to 2021 10.3. Current and Future Market Size (US$ Million) Analysis Forecast By End User, 2022 to 2032 10.3.1. Hospitals 10.3.2. Ambulatory Surgical Centers 10.3.3. Clinics 10.3.4. Community Health Centers 10.3.5. Reference Laboratories 10.4. Market Attractiveness Analysis By End User 11. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by Region 11.1. Introduction 11.2. Historical Market Size (US$ Million) Analysis By Region, 2012 to 2021 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2022 to 2032 11.3.1. North America 11.3.2. Latin America 11.3.3. Europe 11.3.4. East Asia 11.3.5. South Asia 11.3.6. Oceania 11.3.7. Middle East and Africa (MEA) 11.4. Market Attractiveness Analysis By Region 12. North America Market Analysis 2012 to 2021 and Forecast 2022 to 2032 12.1. Introduction 12.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2012 to 2021 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032 12.3.1. By Country 12.3.1.1. United States of America 12.3.1.2. Canada 12.3.2. By Tests Type 12.3.3. By Infection Type 12.3.4. By End User 12.4. Market Attractiveness Analysis 12.4.1. By Country 12.4.2. By Tests Type 12.4.3. By Infection Type 12.4.4. By End User 12.5. Market Trends 12.6. Key Market Participants - Intensity Mapping 12.7. Drivers and Restraints - Impact Analysis 12.8. Country-Level Analysis & Forecast 12.8.1. USA Market Analysis 12.8.1.1. Introduction 12.8.1.2. Market Analysis and Forecast by Market Taxonomy 12.8.1.2.1. By Tests Type 12.8.1.2.2. By Infection Type 12.8.1.2.3. By End User 12.8.2. Canada Market Analysis 12.8.2.1. Introduction 12.8.2.2. Market Analysis and Forecast by Market Taxonomy 12.8.2.2.1. By Tests Type 12.8.2.2.2. By Infection Type 12.8.2.2.3. By End User 13. Latin America Market Analysis 2012 to 2021 and Forecast 2022 to 2032 13.1. Introduction 13.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2012 to 2021 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032 13.3.1. By Country 13.3.1.1. Mexico 13.3.1.2. Brazil 13.3.1.3. Argentina 13.3.1.4. Rest of Latin America 13.3.2. By Tests Type 13.3.3. By Infection Type 13.3.4. By End User 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Tests Type 13.4.3. By Infection Type 13.4.4. By End User 13.5. Market Trends 13.6. Key Market Participants - Intensity Mapping 13.7. Drivers and Restraints - Impact Analysis 13.8. Country-Level Analysis & Forecast 13.8.1. Mexico Market Analysis 13.8.1.1. Introduction 13.8.1.2. Market Analysis and Forecast by Market Taxonomy 13.8.1.2.1. By Tests Type 13.8.1.2.2. By Infection Type 13.8.1.2.3. By End User 13.8.2. Brazil Market Analysis 13.8.2.1. Introduction 13.8.2.2. Market Analysis and Forecast by Market Taxonomy 13.8.2.2.1. By Tests Type 13.8.2.2.2. By Infection Type 13.8.2.2.3. By End User 13.8.3. Argentina Market Analysis 13.8.3.1. Introduction 13.8.3.2. Market Analysis and Forecast by Market Taxonomy 13.8.3.2.1. By Tests Type 13.8.3.2.2. By Infection Type 13.8.3.2.3. By End User 14. Europe Market Analysis 2012 to 2021 and Forecast 2022 to 2032 14.1. Introduction 14.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2012 to 2021 14.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032 14.3.1. By Country 14.3.1.1. Germany 14.3.1.2. Italy 14.3.1.3. France 14.3.1.4. United Kingdom 14.3.1.5. Spain 14.3.1.6. BENELUX 14.3.1.7. Russia 14.3.1.8. Rest of Europe 14.3.2. By Tests Type 14.3.3. By Infection Type 14.3.4. By End User 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Tests Type 14.4.3. By Infection Type 14.4.4. By End User 14.5. Market Trends 14.6. Key Market Participants - Intensity Mapping 14.7. Drivers and Restraints - Impact Analysis 14.8. Country-Level Analysis & Forecast 14.8.1. Germany Market Analysis 14.8.1.1. Introduction 14.8.1.2. Market Analysis and Forecast by Market Taxonomy 14.8.1.2.1. By Tests Type 14.8.1.2.2. By Infection Type 14.8.1.2.3. By End User 14.8.2. Italy Market Analysis 14.8.2.1. Introduction 14.8.2.2. Market Analysis and Forecast by Market Taxonomy 14.8.2.2.1. By Tests Type 14.8.2.2.2. By Infection Type 14.8.2.2.3. By End User 14.8.3. France Market Analysis 14.8.3.1. Introduction 14.8.3.2. Market Analysis and Forecast by Market Taxonomy 14.8.3.2.1. By Tests Type 14.8.3.2.2. By Infection Type 14.8.3.2.3. By End User 14.8.4. UK Market Analysis 14.8.4.1. Introduction 14.8.4.2. Market Analysis and Forecast by Market Taxonomy 14.8.4.2.1. By Tests Type 14.8.4.2.2. By Infection Type 14.8.4.2.3. By End User 14.8.5. Spain Market Analysis 14.8.5.1. Introduction 14.8.5.2. Market Analysis and Forecast by Market Taxonomy 14.8.5.2.1. By Tests Type 14.8.5.2.2. By Infection Type 14.8.5.2.3. By End User 14.8.6. BENELUX Market Analysis 14.8.6.1. Introduction 14.8.6.2. Market Analysis and Forecast by Market Taxonomy 14.8.6.2.1. By Tests Type 14.8.6.2.2. By Infection Type 14.8.6.2.3. By End User 14.8.7. Russia Market Analysis 14.8.7.1. Introduction 14.8.7.2. Market Analysis and Forecast by Market Taxonomy 14.8.7.2.1. By Tests Type 14.8.7.2.2. By Infection Type 14.8.7.2.3. By End User 15. South Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032 15.1. Introduction 15.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2012 to 2021 15.3. Current and Future Market Size (US$ Million) Analysis Forecast By Market Taxonomy, 2022 to 2032 15.3.1. By Country 15.3.1.1. India 15.3.1.2. Indonesia 15.3.1.3. Malaysia 15.3.1.4. Thailand 15.3.1.5. Rest of South Asia 15.3.2. By Tests Type 15.3.3. By Infection Type 15.3.4. By End User 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Tests Type 15.4.3. By Infection Type 15.4.4. By End User 15.5. Market Trends 15.6. Key Market Participants - Intensity Mapping 15.7. Drivers and Restraints - Impact Analysis 15.8. Country-Level Analysis & Forecast 15.8.1. India Market Analysis 15.8.1.1. Introduction 15.8.1.2. Market Analysis and Forecast by Market Taxonomy 15.8.1.2.1. By Tests Type 15.8.1.2.2. By Infection Type 15.8.1.2.3. By End User 15.8.2. Indonesia Market Analysis 15.8.2.1. Introduction 15.8.2.2. Market Analysis and Forecast by Market Taxonomy 15.8.2.2.1. By Tests Type 15.8.2.2.2. By Infection Type 15.8.2.2.3. By End User 15.8.3. Malaysia Market Analysis 15.8.3.1. Introduction 15.8.3.2. Market Analysis and Forecast by Market Taxonomy 15.8.3.2.1. By Tests Type 15.8.3.2.2. By Infection Type 15.8.3.2.3. By End User 15.8.4. Thailand Market Analysis 15.8.4.1. Introduction 15.8.4.2. Market Analysis and Forecast by Market Taxonomy 15.8.4.2.1. By Tests Type 15.8.4.2.2. By Infection Type 15.8.4.2.3. By End User 16. East Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032 16.1. Introduction 16.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2012 to 2021 16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032 16.3.1. By Country 16.3.1.1. China 16.3.1.2. Japan 16.3.1.3. South Korea 16.3.2. By Tests Type 16.3.3. By Infection Type 16.3.4. By End User 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Tests Type 16.4.3. By Infection Type 16.4.4. By End User 16.5. Market Trends 16.6. Key Market Participants - Intensity Mapping 16.7. Drivers and Restraints - Impact Analysis 16.8. Country-Level Analysis & Forecast 16.8.1. China Market Analysis 16.8.1.1. Introduction 16.8.1.2. Market Analysis and Forecast by Market Taxonomy 16.8.1.2.1. By Tests Type 16.8.1.2.2. By Infection Type 16.8.1.2.3. By End User 16.8.2. Japan Market Analysis 16.8.2.1. Introduction 16.8.2.2. Market Analysis and Forecast by Market Taxonomy 16.8.2.2.1. By Tests Type 16.8.2.2.2. By Infection Type 16.8.2.2.3. By End User 16.8.3. South Korea Market Analysis 16.8.3.1. Introduction 16.8.3.2. Market Analysis and Forecast by Market Taxonomy 16.8.3.2.1. By Tests Type 16.8.3.2.2. By Infection Type 16.8.3.3. By End User 17. Oceania Market 2017 to 2021 and Forecast 2022 to 2032 17.1. Introduction 17.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2012 to 2021 17.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032 17.3.1. By Country 17.3.1.1. Australia 17.3.1.2. New Zealand 17.3.2. By Tests Type 17.3.3. By Infection Type 17.3.4. By End User 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Tests Type 17.4.3. By Infection Type 17.4.4. By End User 17.5. Market Trends 17.6. Key Market Participants - Intensity Mapping 17.7. Drivers and Restraints - Impact Analysis 17.8. Country-Level Analysis & Forecast 17.8.1. Australia Market Analysis 17.8.1.1. Introduction 17.8.1.2. Market Analysis and Forecast by Market Taxonomy 17.8.1.2.1. By Tests Type 17.8.1.2.2. By Infection Type 17.8.1.2.3. By End User 17.8.2. New Zealand Market Analysis 17.8.2.1. Introduction 17.8.2.2. Market Analysis and Forecast by Market Taxonomy 17.8.2.2.1. By Tests Type 17.8.2.2.2. By Infection Type 17.8.2.2.3. By End User 18. Middle East and Africa (MEA) Market Analysis 2012 to 2021 and Forecast 2022 to 2032 18.1. Introduction 18.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2012 to 2021 18.3. Current and Future Market Size (US$ Million) Analysis Forecast By Market Taxonomy, 2022 to 2032 18.3.1. By Country 18.3.1.1. GCC Countries 18.3.1.2. Turkey 18.3.1.3. South Africa 18.3.1.4. North Africa 18.3.2. By Tests Type 18.3.3. By Infection Type 18.3.4. By End User 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Tests Type 18.4.3. By Infection Type 18.4.4. By End User 18.5. Market Trends 18.6. Key Market Participants - Intensity Mapping 18.7. Drivers and Restraints - Impact Analysis 18.8. Country-Level Analysis & Forecast 18.8.1. GCC Countries Market Analysis 18.8.1.1. Introduction 18.8.1.2. Market Analysis and Forecast by Market Taxonomy 18.8.1.2.1. By Tests Type 18.8.1.2.2. By Infection Type 18.8.1.2.3. By End User 18.8.2. Turkey Market Analysis 18.8.2.1. Introduction 18.8.2.2. Market Analysis and Forecast by Market Taxonomy 18.8.2.2.1. By Tests Type 18.8.2.2.2. By Infection Type 18.8.2.2.3. By End User 18.8.3. South Africa Market Analysis 18.8.3.1. Introduction 18.8.3.2. Market Analysis and Forecast by Market Taxonomy 18.8.3.2.1. By Tests Type 18.8.3.2.2. By Infection Type 18.8.3.2.3. By End User 18.8.4. North Africa Market Analysis 18.8.4.1. Introduction 18.8.4.2. Market Analysis and Forecast by Market Taxonomy 18.8.4.2.1. By Tests Type 18.8.4.2.2. By Infection Type 18.8.4.2.3. By End User 19. Market Structure Analysis 19.1. Market Analysis by Tier of Companies 19.2. Market Share Analysis of Top Players 19.3. Market Presence Analysis 20. Competition Analysis 20.1. Competition Dashboard 20.2. Competition Benchmarking 20.3. Competition Deep Dive 20.3.1. Abbott Laboratories 20.3.1.1. Overview 20.3.1.2. Product Portfolio 20.3.1.3. Fey Financials 20.3.1.4. Sales Footprint 20.3.1.5. Strategy Overview 20.3.2. bioMérieux SA, 20.3.2.1. Overview 20.3.2.2. Product Portfolio 20.3.2.3. Fey Financials 20.3.2.4. Sales Footprint 20.3.2.5. Strategy Overview 20.3.3. Bio-Rad Laboratories Inc., 20.3.3.1. Overview 20.3.3.2. Product Portfolio 20.3.3.3. Fey Financials 20.3.3.4. Sales Footprint 20.3.3.5. Strategy Overview 20.3.4. Bruker Corporation, 20.3.4.1. Overview 20.3.4.2. Product Portfolio 20.3.4.3. Fey Financials 20.3.4.4. Sales Footprint 20.3.4.5. Strategy Overview 20.3.5. Danaher Corporation, 20.3.5.1. Overview 20.3.5.2. Product Portfolio 20.3.5.3. Fey Financials 20.3.5.4. Sales Footprint 20.3.5.5. Strategy Overview 20.3.6. Erba Mannheim, 20.3.6.1. Overview 20.3.6.2. Product Portfolio 20.3.6.3. Fey Financials 20.3.6.4. Sales Footprint 20.3.6.5. Strategy Overview 20.3.7. F. Hoffmann-La Roche AG, 20.3.7.1. Overview 20.3.7.2. Product Portfolio 20.3.7.3. Fey Financials 20.3.7.4. Sales Footprint 20.3.7.5. Strategy Overview 20.3.8. Luminex Corporation, 20.3.8.1. Overview 20.3.8.2. Product Portfolio 20.3.8.3. Fey Financials 20.3.8.4. Sales Footprint 20.3.8.5. Strategy Overview 20.3.9. Meridian Bioscience Inc., 20.3.9.1. Overview 20.3.9.2. Product Portfolio 20.3.9.3. Fey Financials 20.3.9.4. Sales Footprint 20.3.9.5. Strategy Overview 20.3.10. Norgen Biotek Corp., 20.3.10.1. Overview 20.3.10.2. Product Portfolio 20.3.10.3. Fey Financials 20.3.10.4. Sales Footprint 20.3.10.5. Strategy Overview 20.3.11. Omega Diagnostics Group Plc., 20.3.11.1. Overview 20.3.11.2. Product Portfolio 20.3.11.3. Fey Financials 20.3.11.4. Sales Footprint 20.3.11.5. Strategy Overview 20.3.12. Qiagen N.V., 20.3.12.1. Overview 20.3.12.2. Product Portfolio 20.3.12.3. Fey Financials 20.3.12.4. Sales Footprint 20.3.12.5. Strategy Overview 20.3.13. Quidel Corporation, 20.3.13.1. Overview 20.3.13.2. Product Portfolio 20.3.13.3. Fey Financials 20.3.13.4. Sales Footprint 20.3.13.5. Strategy Overview 20.3.14. Thermo Fisher Scientific Inc. 20.3.14.1. Overview 20.3.14.2. Product Portfolio 20.3.14.3. Fey Financials 20.3.14.4. Sales Footprint 20.3.14.5. Strategy Overview 21. Assumptions and Acronyms Used 22. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 01: Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by Test Table 02: Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032 by Infection Table 03: Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by End User Table 04: Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by Region Table 05: North America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country Table 06: North America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Test Table 07: North America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Infection Table 08: North America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by End User Table 09: Latin America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country Table 10: Latin America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Test Table 11: Latin America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Infection Table 12: Latin America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by End User Table 13: Europe Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country Table 14: Europe Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Test Table 15: Europe Market Analysis 2012 to 2021 and Forecast 2022 to 2032 by Infection Table 16: Europe Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by End User Table 17: East Asia Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country Table 18: East Asia Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Test Table 19: East Asia Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Infection Table 20: East Asia Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by End User Table 21: South Asia Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country Table 22: South Asia Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Test Table 23: South Asia Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Infection Table 24: South Asia Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by End User Table 25: Oceania Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country Table 26: Oceania Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Test Table 27: Oceania Market Analysis 2012 to 2021 and Forecast 2022 to 2032by Infection Table 28: Oceania Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by End User Table 29: Middle East & Africa Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country Table 30: Middle East & Africa Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Test Table 31: Middle East & Africa Market Analysis 2012 to 2021 and Forecast 2022 to 2032by Infection Table 32: Middle East & Africa Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by End User
List of Charts
Figure 01: Global Market Value (US$ Million) Analysis, 2012 to 2021 Figure 02: Global Market Forecast & Y-o-Y Growth, 2022 to 2032 Figure 03: Global Market Absolute $ Opportunity (US$ Million) Analysis, 2021 to 2032 Figure 04: Global Market Value Share (%) Analysis 2022 and 2032, by Test Figure 05: Global Market Y-o-Y Growth (%) Analysis 2022 to 2032, by Test Figure 06: Global Market Attractiveness Analysis 2022 to 2032, by Test Figure 07: Global Market Value Share (%) Analysis 2022 and 2032, by Infection Figure 08: Global Market Y-o-Y Growth (%) Analysis 2022 to 2032, by Infection Figure 09: Global Market Attractiveness Analysis 2022 to 2032, by Infection Figure 10: Global Market Value Share (%) Analysis 2022 and 2032, by End User Figure 11: Global Market Y-o-Y Growth (%) Analysis 2022 to 2032, by End User Figure 12: Global Market Attractiveness Analysis 2022 to 2032, by End User Figure 13: Global Market Value Share (%) Analysis 2022 and 2032, by Region Figure 14: Global Market Y-o-Y Growth (%) Analysis 2022 to 2032, by Region Figure 15: Global Market Attractiveness Analysis 2022 to 2032, by Region Figure 16: North America Market Value (US$ Million) Analysis, 2012 to 2021 Figure 17: North America Market Value (US$ Million) Forecast, 2022 to 2032 Figure 18: North America Market Value Share, by Test (2022 E) Figure 19: North America Market Value Share, by Infection (2022 E) Figure 20: North America Market Value Share, by End User (2022 E) Figure 21: North America Market Value Share, by Country (2022 E) Figure 22: North America Market Attractiveness Analysis by Test, 2022 to 2032 Figure 23: North America Market Attractiveness Analysis by Infection, 2022 to 2032 Figure 24: North America Market Attractiveness Analysis by End User, 2022 to 2032 Figure 25: North America Market Attractiveness Analysis by Country, 2022 to 2032 Figure 26: USA Market Value Proportion Analysis, 2021 Figure 27: Global Vs. USA Growth Comparison, 2021 to 2032 Figure 28: USA Market Share Analysis (%) by Test, 2021 to 2032 Figure 29: USA Market Share Analysis (%) by Infection, 2021 to 2032 Figure 30: USA Market Share Analysis (%) by End User, 2021 to 2032 Figure 31: Canada Market Value Proportion Analysis, 2021 Figure 32: Global Vs. Canada. Growth Comparison, 2021 to 2032 Figure 33: Canada Market Share Analysis (%) by Test, 2021 to 2032 Figure 34: Canada Market Share Analysis (%) by Infection, 2021 to 2032 Figure 35: Canada Market Share Analysis (%) by End User, 2021 to 2032 Figure 36: Latin America Market Value (US$ Million) Analysis, 2012 to 2021 Figure 37: Latin America Market Value (US$ Million) Forecast, 2022 to 2032 Figure 38: Latin America Market Value Share, by Test (2022 E) Figure 39: Latin America Market Value Share, by Infection (2022 E) Figure 40: Latin America Market Value Share, by End User (2022 E) Figure 41: Latin America Market Value Share, by Country (2022 E) Figure 42: Latin America Market Attractiveness Analysis by Test, 2022 to 2032 Figure 43: Latin America Market Attractiveness Analysis by Infection, 2022 to 2032 Figure 44: Latin America Market Attractiveness Analysis by End User, 2022 to 2032 Figure 45: Latin America Market Attractiveness Analysis by Country, 2022 to 2032 Figure 46: Mexico Market Value Proportion Analysis, 2021 Figure 47: Global Vs Mexico Growth Comparison, 2021 to 2032 Figure 48: Mexico Market Share Analysis (%) by Test, 2021 to 2032 Figure 49: Mexico Market Share Analysis (%) by Infection, 2021 to 2032 Figure 50: Mexico Market Share Analysis (%) by End User, 2021 to 2032 Figure 51: Brazil Market Value Proportion Analysis, 2021 Figure 52: Global Vs. Brazil. Growth Comparison, 2021 to 2032 Figure 53: Brazil Market Share Analysis (%) by Test, 2021 to 2032 Figure 54: Brazil Market Share Analysis (%) by Infection, 2021 to 2032 Figure 55: Brazil Market Share Analysis (%) by End User, 2021 to 2032 Figure 56: Argentina Market Value Proportion Analysis, 2021 Figure 57: Global Vs Argentina Growth Comparison, 2021 to 2032 Figure 58: Argentina Market Share Analysis (%) by Test, 2021 to 2032 Figure 59: Argentina Market Share Analysis (%) by Infection, 2021 to 2032 Figure 60: Argentina Market Share Analysis (%) by End User, 2021 to 2032 Figure 61: Europe Market Value (US$ Million) Analysis, 2012 to 2021 Figure 62: Europe Market Value (US$ Million) Forecast, 2022 to 2032 Figure 63: Europe Market Value Share, by Test (2022 E) Figure 64: Europe Market Value Share, by Infection (2022 E) Figure 65: Europe Market Value Share, by End User (2022 E) Figure 66: Europe Market Value Share, by Country (2022 E) Figure 67: Europe Market Attractiveness Analysis by Test, 2022 to 2032 Figure 68: Europe Market Attractiveness Analysis by Infection, 2022 to 2032 Figure 69: Europe Market Attractiveness Analysis by End User, 2022 to 2032 Figure 70: Europe Market Attractiveness Analysis by Country, 2022 to 2032 Figure 71: UK Market Value Proportion Analysis, 2021 Figure 72: Global Vs. UK Growth Comparison, 2021 to 2032 Figure 73: UK Market Share Analysis (%) by Test, 2021 to 2032 Figure 74: UK Market Share Analysis (%) by Infection, 2021 to 2032 Figure 75: UK Market Share Analysis (%) by End User, 2021 to 2032 Figure 76: Germany Market Value Proportion Analysis, 2021 Figure 77: Global Vs. Germany Growth Comparison, 2021 to 2032 Figure 78: Germany Market Share Analysis (%) by Test, 2021 to 2032 Figure 79: Germany Market Share Analysis (%) by Infection, 2021 to 2032 Figure 80: Germany Market Share Analysis (%) by End User, 2021 to 2032 Figure 81: Italy Market Value Proportion Analysis, 2021 Figure 82: Global Vs. Italy Growth Comparison, 2021 to 2032 Figure 83: Italy Market Share Analysis (%) by Test, 2021 to 2032 Figure 84: Italy Market Share Analysis (%) by Infection, 2021 to 2032 Figure 85: Italy Market Share Analysis (%) by End User, 2021 to 2032 Figure 86: France Market Value Proportion Analysis, 2021 Figure 87: Global Vs France Growth Comparison, 2021 to 2032 Figure 88: France Market Share Analysis (%) by Test, 2021 to 2032 Figure 89: France Market Share Analysis (%) by Infection, 2021 to 2032 Figure 90: France Market Share Analysis (%) by End User, 2021 to 2032 Figure 91: Spain Market Value Proportion Analysis, 2021 Figure 92: Global Vs Spain Growth Comparison, 2021 to 2032 Figure 93: Spain Market Share Analysis (%) by Test, 2021 to 2032 Figure 94: Spain Market Share Analysis (%) by Infection, 2021 to 2032 Figure 95: Spain Market Share Analysis (%) by End User, 2021 to 2032 Figure 96: Russia Market Value Proportion Analysis, 2021 Figure 97: Global Vs Russia Growth Comparison, 2021 to 2032 Figure 98: Russia Market Share Analysis (%) by Test, 2021 to 2032 Figure 99: Russia Market Share Analysis (%) by Infection, 2021 to 2032 Figure 100: Russia Market Share Analysis (%) by End User, 2021 to 2032 Figure 101: BENELUX Market Value Proportion Analysis, 2021 Figure 102: Global Vs BENELUX Growth Comparison, 2021 to 2032 Figure 103: BENELUX Market Share Analysis (%) by Test, 2021 to 2032 Figure 104: BENELUX Market Share Analysis (%) by Infection, 2021 to 2032 Figure 105: BENELUX Market Share Analysis (%) by End User, 2021 to 2032 Figure 106: East Asia Market Value (US$ Million) Analysis, 2012 to 2021 Figure 107: East Asia Market Value (US$ Million) Forecast, 2022 to 2032 Figure 108: East Asia Market Value Share, by Test (2022 E) Figure 109: East Asia Market Value Share, by Infection (2022 E) Figure 110: East Asia Market Value Share, by End User (2022 E) Figure 111: East Asia Market Value Share, by Country (2022 E) Figure 112: East Asia Market Attractiveness Analysis by Test, 2022 to 2032 Figure 113: East Asia Market Attractiveness Analysis by Infection, 2022 to 2032 Figure 114: East Asia Market Attractiveness Analysis by End User, 2022 to 2032 Figure 115: East Asia Market Attractiveness Analysis by Country, 2022 to 2032 Figure 116: China Market Value Proportion Analysis, 2021 Figure 117: Global Vs. China Growth Comparison, 2021 to 2032 Figure 118: China Market Share Analysis (%) by Test, 2021 to 2032 Figure 119: China Market Share Analysis (%) by Infection, 2021 to 2032 Figure 120: China Market Share Analysis (%) by End User, 2021 to 2032 Figure 121: Japan Market Value Proportion Analysis, 2021 Figure 122: Global Vs. Japan Growth Comparison, 2021 to 2032 Figure 123: Japan Market Share Analysis (%) by Test, 2021 to 2032 Figure 124: Japan Market Share Analysis (%) by Infection, 2021 to 2032 Figure 125: Japan Market Share Analysis (%) by End User, 2021 to 2032 Figure 126: South Korea Market Value Proportion Analysis, 2021 Figure 127: Global Vs South Korea Growth Comparison, 2021 to 2032 Figure 128: South Korea Market Share Analysis (%) by Test, 2021 to 2032 Figure 129: South Korea Market Share Analysis (%) by Infection, 2021 to 2032 Figure 130: South Korea Market Share Analysis (%) by End User, 2021 to 2032 Figure 131: South Asia Market Value (US$ Million) Analysis, 2012 to 2021 Figure 132: South Asia Market Value (US$ Million) Forecast, 2022 to 2032 Figure 133: South Asia Market Value Share, by Test (2022 E) Figure 134: South Asia Market Value Share, by Infection (2022 E) Figure 135: South Asia Market Value Share, by End User (2022 E) Figure 136: South Asia Market Value Share, by Country (2022 E) Figure 137: South Asia Market Attractiveness Analysis by Test, 2022 to 2032 Figure 138: South Asia Market Attractiveness Analysis by Infection, 2022 to 2032 Figure 139: South Asia Market Attractiveness Analysis by End User, 2022 to 2032 Figure 140: South Asia Market Attractiveness Analysis by Country, 2022 to 2032 Figure 141: India Market Value Proportion Analysis, 2021 Figure 142: Global Vs. India Growth Comparison, 2021 to 2032 Figure 143: India Market Share Analysis (%) by Test, 2021 to 2032 Figure 144: India Market Share Analysis (%) by Infection, 2021 to 2032 Figure 145: India Market Share Analysis (%) by End User, 2021 to 2032 Figure 146: Indonesia Market Value Proportion Analysis, 2021 Figure 147: Global Vs. Indonesia Growth Comparison, 2021 to 2032 Figure 148: Indonesia Market Share Analysis (%) by Test, 2021 to 2032 Figure 149: Indonesia Market Share Analysis (%) by Infection, 2021 to 2032 Figure 150: Indonesia Market Share Analysis (%) by End User, 2021 to 2032 Figure 151: Malaysia Market Value Proportion Analysis, 2021 Figure 152: Global Vs. Malaysia Growth Comparison, 2021 to 2032 Figure 153: Malaysia Market Share Analysis (%) by Test, 2021 to 2032 Figure 154: Malaysia Market Share Analysis (%) by Infection, 2021 to 2032 Figure 155: Malaysia Market Share Analysis (%) by End User, 2021 to 2032 Figure 156: Thailand Market Value Proportion Analysis, 2021 Figure 157: Global Vs. Thailand Growth Comparison, 2021 to 2032 Figure 158: Thailand Market Share Analysis (%) by Test, 2021 to 2032 Figure 159: Thailand Market Share Analysis (%) by Infection, 2021 to 2032 Figure 160: Thailand Market Share Analysis (%) by End User, 2021 to 2032 Figure 161: Oceania Market Value (US$ Million) Analysis, 2012 to 2021 Figure 162: Oceania Market Value (US$ Million) Forecast, 2022 to 2032 Figure 163: Oceania Market Value Share, by Test (2022 E) Figure 164: Oceania Market Value Share, by Infection (2022 E) Figure 165: Oceania Market Value Share, by End User (2022 E) Figure 166: Oceania Market Value Share, by Country (2022 E) Figure 167: Oceania Market Attractiveness Analysis by Test, 2022 to 2032 Figure 168: Oceania Market Attractiveness Analysis by Infection, 2022 to 2032 Figure 169: Oceania Market Attractiveness Analysis by End User, 2022 to 2032 Figure 170: Oceania Market Attractiveness Analysis by Country, 2022 to 2032 Figure 171: Australia Market Value Proportion Analysis, 2021 Figure 172: Global Vs. Australia Growth Comparison, 2021 to 2032 Figure 173: Australia Market Share Analysis (%) by Test, 2021 to 2032 Figure 174: Australia Market Share Analysis (%) by Infection, 2021 to 2032 Figure 175: Australia Market Share Analysis (%) by End User, 2021 to 2032 Figure 176: New Zealand Market Value Proportion Analysis, 2021 Figure 177: Global Vs New Zealand Growth Comparison, 2021 to 2032 Figure 178: New Zealand Market Share Analysis (%) by Test, 2021 to 2032 Figure 179: New Zealand Market Share Analysis (%) by Infection, 2021 to 2032 Figure 180: New Zealand Market Share Analysis (%) by End User, 2021 to 2032 Figure 181: Middle East & Africa Market Value (US$ Million) Analysis, 2012 to 2021 Figure 182: Middle East & Africa Market Value (US$ Million) Forecast, 2022 to 2032 Figure 183: Middle East & Africa Market Value Share, by Test (2022 E) Figure 184: Middle East & Africa Market Value Share, by Infection (2022 E) Figure 185: Middle East & Africa Market Value Share, by End User (2022 E) Figure 186: Middle East & Africa Market Value Share, by Country (2022 E) Figure 187: Middle East & Africa Market Attractiveness Analysis by Test, 2022 to 2032 Figure 188: Middle East & Africa Market Attractiveness Analysis by Infection, 2022 to 2032 Figure 189: Middle East & Africa Market Attractiveness Analysis by End User, 2022 to 2032 Figure 190: Middle East & Africa Market Attractiveness Analysis by Country, 2022 to 2032 Figure 191: GCC Countries Market Value Proportion Analysis, 2021 Figure 192: Global Vs GCC Countries Growth Comparison, 2021 to 2032 Figure 193: GCC Countries Market Share Analysis (%) by Test, 2021 to 2032 Figure 194: GCC Countries Market Share Analysis (%) by Infection, 2021 to 2032 Figure 195: GCC Countries Market Share Analysis (%) by End User, 2021 to 2032 Figure 196: Turkey Market Value Proportion Analysis, 2021 Figure 197: Global Vs. Turkey Growth Comparison, 2021 to 2032 Figure 198: Turkey Market Share Analysis (%) by Test, 2021 to 2032 Figure 199: Turkey Market Share Analysis (%) by Infection, 2021 to 2032 Figure 200: Turkey Market Share Analysis (%) by End User, 2021 to 2032 Figure 201: South Africa Market Value Proportion Analysis, 2021 Figure 202: Global Vs. South Africa Growth Comparison, 2021 to 2032 Figure 203: South Africa Market Share Analysis (%) by Test, 2021 to 2032 Figure 204: South Africa Market Share Analysis (%) by Infection, 2021 to 2032 Figure 205: South Africa Market Share Analysis (%) by End User, 2021 to 2032 Figure 206: North Africa Market Value Proportion Analysis, 2021 Figure 207: Global Vs North Africa Growth Comparison, 2021 to 2032 Figure 208: North Africa Market Share Analysis (%) by Test, 2021 to 2032 Figure 209: North Africa Market Share Analysis (%) by Infection, 2021 to 2032 Figure 210: North Africa Market Share Analysis (%) by End User, 2021 to 2032
Recommendations
Explore Healthcare Insights
View Reports